J. Goldman & Co’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$326K Sell
69,452
-257,893
-79% -$1.34M 0.01% 658
2026
Q2
$1.54M Buy
+327,345
New +$2.41M 0.04% 391

Other funds holding UNCY

J. Goldman & Co's UNCY Position: Q3 2026 in Review

J. Goldman & Co reduced its Unicycive Therapeutics (UNCY) stake by 79% in Q3 2026, selling an estimated $1.34M and leaving 69,452 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #658.

J. Goldman & Co first reported a position in UNCY in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.54M in Q2 2026. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • J. Goldman & Co held 69,452 shares of Unicycive Therapeutics worth $326K as of Q3 2026.
  • J. Goldman & Co sold 257,893 Unicycive Therapeutics shares in Q3 2026, an estimated $1.34M.
  • Unicycive Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q3 2026, its #658 holding.
  • J. Goldman & Co first reported a position in Unicycive Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • J. Goldman & Co's Unicycive Therapeutics position peaked at $1.54M in Q2 2026.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on J. Goldman & Co's 13F filing for Q3 2026, filed 16 Nov 2026.